BiomX (PHGE) Q4 2025 earnings summary

Executive summary

• Clinical-stage company focused on phage-based therapies for chronic bacterial diseases, with no approved products or product revenue as of year-end 2025.

• Discontinued lead cystic fibrosis program (BX004) and entered insolvency proceedings for Israeli subsidiary, resulting in significant operational downsizing.

• Entered a Securities Purchase Agreement in December 2025 for $3.0 million in gross proceeds, contingent on stockholder approval, which may result in a change of control.

• Actively evaluating strategic alternatives due to limited resources and ongoing financial uncertainty.

Financial highlights

• Net loss for 2025 was $36.2 million, compared to $17.7 million in 2024.

• Accumulated deficit reached $216.9 million as of December 31, 2025.

• Cash, cash equivalents, and restricted cash totaled $5.0 million at year-end 2025.

• R&D expenses (net) were $21.3 million, down 14% from $24.7 million in 2024, mainly due to workforce reduction.

• General and administrative expenses were $9.6 million, a 19% decrease from 2024.

• Impairment charges in 2025 included $11.8 million for IPR&D and $1.7 million for other long-lived assets.

• Income from change in fair value of warrants was $6.1 million, down from $26.5 million in 2024.

Outlook and guidance

• Current funds, including recent financing, are expected to last only through the end of Q2 2026.

• Continuation as a going concern is dependent on raising additional capital and obtaining stockholder approval for the recent financing.

• Actively pursuing strategic alternatives, with future expenses expected to remain substantial if operations continue.